A possible association between survival time and transfusion in cervical cancer
- PMID: 3242314
- PMCID: PMC2590486
A possible association between survival time and transfusion in cervical cancer
Abstract
Some studies suggest that transfusion may be associated with an increased risk of recurrence of and death due to malignant human neoplasms. We examined retrospective data from patients with cervical cancer to see if any association between transfusion of blood at the time of initial treatment and the time interval to recurrence and death could be detected in this cancer. In 130 patients with cervical cancer, seen over a ten-year period at our institution, there was a trend toward earlier recurrence in transfused patients, but this trend did not achieve statistical significance. Death due to cervical cancer recurrence occurred after a median of Death due to cervical cancer recurrence occurred after a median of 12 months in the transfused patients and a median of 68 months in the non-transfused individuals, which was statistically significant. Transfused patients had, on average, more favorable prognostic factors than those not transfused, such as less advanced clinical stage of disease. Analysis using a proportional hazards risk model failed to demonstrate a significant association between transfusion and time to recurrence when other prognostic factors were considered, but a significant association between transfusion and time to cancer-related death (p less than 0.05) was found. While these results cannot be viewed as conclusive due to the small number and heterogeneity of the patients analyzed, our data support the possibility of an association between transfusion and cervical cancer survival. Further studies are warranted to confirm or refute this relationship.
Similar articles
-
Blood transfusion and the risk of recurrence in stage IB cervical cancer.Gynecol Oncol. 1995 Jun;57(3):401-6. doi: 10.1006/gyno.1995.1162. Gynecol Oncol. 1995. PMID: 7774845
-
Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy?Obstet Gynecol. 1995 Mar;85(3):343-8. doi: 10.1016/0029-7844(94)00398-W. Obstet Gynecol. 1995. PMID: 7862369 Clinical Trial.
-
Patterns of spread in node-positive cervical cancer: the relationship between local control and distant metastases.Cancer J Sci Am. 1996 Sep-Oct;2(5):256-62. Cancer J Sci Am. 1996. PMID: 9166542
-
Association of transfusion with postoperative bacterial infection.Crit Rev Clin Lab Sci. 1990;28(2):95-107. doi: 10.3109/10408369009105899. Crit Rev Clin Lab Sci. 1990. PMID: 2073350 Review.
-
[Recurrence of uterine cervical cancer more than 5 years after initial therapy].Nihon Rinsho. 2004 Oct;62 Suppl 10:230-2. Nihon Rinsho. 2004. PMID: 15535241 Review. Japanese. No abstract available.
Cited by
-
Anemia in cervical cancer patients: implications for iron supplementation therapy.Med Oncol. 2005;22(2):161-8. doi: 10.1385/MO:22:2:161. Med Oncol. 2005. PMID: 15965279 Clinical Trial.
-
Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.Br J Cancer. 1998 Jun;77(11):1996-2002. doi: 10.1038/bjc.1998.331. Br J Cancer. 1998. PMID: 9667681 Free PMC article. Clinical Trial.
-
Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis.World J Surg. 2008 Sep;32(9):2038-46. doi: 10.1007/s00268-008-9675-9. World J Surg. 2008. PMID: 18584239
-
Dietary and prophylactic iron supplements : Helpful or harmful?Hum Nat. 1990 Mar;1(1):53-79. doi: 10.1007/BF02692146. Hum Nat. 1990. PMID: 24222023